Bögemann, Martin
Facchini, Gaetano
Bauernhofer, Thomas
Cathomas, Richard
Xylinas, Evanguelos
Tombal, Bertrand
Funding for this research was provided by:
Westfälische Wilhelms-Universität Münster
Article History
Received: 25 November 2022
Accepted: 30 January 2023
First Online: 22 March 2023
Declarations
:
: M. Bögemann is an employee of Janssen; reports receiving grants from Astellas, Ipsen, and Janssen; reports consultancies/honoraria from AAA, Amgen, Astellas, AstraZeneca, Bayer, BMS, Exelixis, Janssen, Lilly, MSD, Novartis, Roche, and Sanofi. G. Facchini reports consultancies/honoraria from Amgen, Astellas, AstraZeneca, Bayer, BMS, Ipsen, and Janssen. T. Bauernhofer reports consultancies and honoraria for lectures from Astellas, AstraZeneca, BMS, Janssen, Merck, and MSD; and a grant from AstraZeneca. R. Cathomas reports being on an advisory board for Astellas, AstraZeneca, Bayer, BMS, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Roche, and Sanofi. E. Xylinas reports consultancies/honoraria for Astellas, AstraZeneca, Bayer, BMS, Janssen, MSD, and Pfizer. B. Tombal reports being an advisor and or investigator for Amgen, Astellas, AstraZeneca, Bayer, Ferring, MSD, Novartis, Janssen, and Pfizer.